FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1840-1842 December 9, 1999 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Jha, T.K. PubMed Citation

Miltefosine was originally developed as an antineoplastic drug, but it has the potential to become the first highly effective, orally administered drug for treating visceral leishmaniasis, a life-threatening parasitic disease. We do not know whether additional clinical trials and experience with miltefosine will support the encouraging findings of the phase 2 study described by Jha et al. in this issue of the Journal.¹ However, the prospect of a new drug that is administered orally rather than parenterally is good news indeed, because the drug could markedly facilitate the treatment of patients.

Although asymptomatic or subclinical infection is common in some . . . [Full Text of this Article]

References

Related Letters:

Miltefosine for Visceral Leishmaniasis
Eibl H., Sherwood J. A., Berman J., Herwaldt B. L.
Extract | Full Text  
N Engl J Med 2000; 342:894-895, Mar 23, 2000. Correspondence

This article has been cited by other articles:

• Verma, N. K., Dey, C. S. (2004). Possible Mechanism of Miltefosine-Mediated Death of Leishmania donovani. Antimicrob. Agents Chemother. 48: 3010-3015 [Abstract] [Full Text]  
• Larabi, M., Yardley, V., Loiseau, P. M., Appel, M., Legrand, P., Gulik, A., Bories, C., Croft, S. L., Barratt, G. (2003). Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B. Antimicrob. Agents Chemother. 47: 3774-3779 [Abstract] [Full Text]  
• Hanson, P. K., Malone, L., Birchmore, J. L., Nichols, J. W. (2003). Lem3p Is Essential for the Uptake and Potency of Alkylphosphocholine Drugs, Edelfosine and Miltefosine. J. Biol. Chem. 278: 36041-36050 [Abstract] [Full Text]  
• Patel, V., Lahusen, T., Sy, T., Sausville, E. A., Gutkind, J. S., Senderowicz, A. M. (2002). Perifosine, a Novel Alkylphospholipid, Induces p21WAF1 Expression in Squamous Carcinoma Cells through a p53-independent Pathway, Leading to Loss in Cyclin-dependent Kinase Activity and Cell Cycle Arrest. Cancer Res. 62: 1401-1409 [Abstract] [Full Text]  
• Herwaldt, B. L. (2001). Laboratory-Acquired Parasitic Infections from Accidental Exposures. Clin. Microbiol. Rev. 14: 659-688 [Abstract] [Full Text]  
• Sundar, S., Agrawal, G, Rai, M., Makharia, M K, Murray, H. W, Lockwood, D. N J (2001). Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial Commentary: cost and resistance remain issues. BMJ 323: 419-422 [Abstract] [Full Text]  
• Eibl, H., Sherwood, J. A., Berman, J., Herwaldt, B. L. (2000). Miltefosine for Visceral Leishmaniasis. NEJM 342: 894-895 [Full Text]  
• (2000). Miltefosine: Oral Therapy for Kala-Azar at Last?. JWatch Infect. Diseases 2000: 10-10 [Full Text]  
• Hanus, L., Abu-Lafi, S., Fride, E., Breuer, A., Vogel, Z., Shalev, D. E., Kustanovich, I., Mechoulam, R. (2001). 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98: 3662-3665 [Abstract] [Full Text]